Bone and fat hormonal crosstalk with antiretroviral initiation.
Antiretrovirals
Bone
Fat
HIV
Leptin
Osteocalcin
Journal
Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
15
03
2021
revised:
16
08
2021
accepted:
15
09
2021
pubmed:
22
9
2021
medline:
12
3
2022
entrez:
21
9
2021
Statut:
ppublish
Résumé
Bone mineral density (BMD) loss and fat gain is common in people living with HIV (PLWH), particularly after initiating combination antiretroviral therapy (cART). Given the close metabolic interaction between bone and fat, we tested the hypotheses that changes in bone-derived hormones are associated with fat accumulation and changes in fat-derived hormones are associated with BMD loss following cART initiation. HIV-seropositive subjects (n = 15) initiating fixed dose cART of tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) underwent dual X-ray absorptiometry (DXA) assessment pre-cART and again 12-months post-cART initiation. DXA-derived measurements included BMD at the lumbar spine, femoral neck, total hip, and trochanter and the trunk and total fat. Serum undercarboxylated osteocalcin (ucOCN), sclerostin, lipocalin-2, leptin, and adiponectin were measured pre and post-cART. Spearman's rank-order correlations assessed the cross-sectional associations between hormones and bone and fat mass pre- and post-cART. Linear regression models adjusting for baseline bone or fat mass assessed the association between hormone change and BMD/fat changes following cART initiation. ucOCN (p = 0.04) and lipocalin-2 (p = 0.03) increased post-cART while sclerostin, leptin, and adiponectin remained unchanged. BMD significantly decreased post-cART at all skeletal sites. Trunk and total fat increased post-cART but not significantly, while weight and BMI remained unchanged. In models adjusting for baseline BMD and fat mass, change in ucOCN was negatively associated with change in trunk (p = 0.008) and total fat (p = 0.01) and the change in leptin was positively associated with change in total hip (p = 0.03) and trochanteric BMD (p = 0.02). The current study demonstrates bone-fat crosstalk in cART initiating PLWH.
Sections du résumé
BACKGROUND
Bone mineral density (BMD) loss and fat gain is common in people living with HIV (PLWH), particularly after initiating combination antiretroviral therapy (cART). Given the close metabolic interaction between bone and fat, we tested the hypotheses that changes in bone-derived hormones are associated with fat accumulation and changes in fat-derived hormones are associated with BMD loss following cART initiation.
METHODS
HIV-seropositive subjects (n = 15) initiating fixed dose cART of tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) underwent dual X-ray absorptiometry (DXA) assessment pre-cART and again 12-months post-cART initiation. DXA-derived measurements included BMD at the lumbar spine, femoral neck, total hip, and trochanter and the trunk and total fat. Serum undercarboxylated osteocalcin (ucOCN), sclerostin, lipocalin-2, leptin, and adiponectin were measured pre and post-cART. Spearman's rank-order correlations assessed the cross-sectional associations between hormones and bone and fat mass pre- and post-cART. Linear regression models adjusting for baseline bone or fat mass assessed the association between hormone change and BMD/fat changes following cART initiation.
RESULTS
ucOCN (p = 0.04) and lipocalin-2 (p = 0.03) increased post-cART while sclerostin, leptin, and adiponectin remained unchanged. BMD significantly decreased post-cART at all skeletal sites. Trunk and total fat increased post-cART but not significantly, while weight and BMI remained unchanged. In models adjusting for baseline BMD and fat mass, change in ucOCN was negatively associated with change in trunk (p = 0.008) and total fat (p = 0.01) and the change in leptin was positively associated with change in total hip (p = 0.03) and trochanteric BMD (p = 0.02).
CONCLUSION
The current study demonstrates bone-fat crosstalk in cART initiating PLWH.
Identifiants
pubmed: 34547525
pii: S8756-3282(21)00374-4
doi: 10.1016/j.bone.2021.116208
pmc: PMC8671338
mid: NIHMS1743835
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Emtricitabine
G70B4ETF4S
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
116208Subventions
Organisme : NIAID NIH HHS
ID : K23 AI059884
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI155230
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI065200
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
J Acquir Immune Defic Syndr. 2004 May 1;36(1):645-7
pubmed: 15097312
J Acquir Immune Defic Syndr. 2021 Apr 15;86(5):e139-e145
pubmed: 33399313
J Bone Miner Res. 2011 Jul;26(7):1568-76
pubmed: 21312272
Nephrol Dial Transplant. 2012 Jan;27(1):226-30
pubmed: 21613383
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5266-70
pubmed: 18362359
Curr Osteoporos Rep. 2020 Aug;18(4):388-400
pubmed: 32529456
J Clin Endocrinol Metab. 2012 Jan;97(1):148-54
pubmed: 21994959
Bone. 2003 Oct;33(4):646-51
pubmed: 14555270
Trends Mol Med. 2010 May;16(5):218-29
pubmed: 20400373
AIDS Res Treat. 2012;2012:103072
pubmed: 22966425
J Clin Endocrinol Metab. 2002 Mar;87(3):1030-5
pubmed: 11889157
Bone. 2020 Sep;138:115509
pubmed: 32599222
Osteoporos Int. 2016 Jul;27(7):2301-2309
pubmed: 27007475
J Bone Miner Res. 2002 Oct;17(10):1896-903
pubmed: 12369793
Exp Cell Res. 2005 Sep 10;309(1):99-109
pubmed: 15963981
Bone. 2001 Jan;28(1):113-7
pubmed: 11165951
Metabolism. 2009 May;58(5):638-43
pubmed: 19375586
Int J Endocrinol. 2013;2013:846480
pubmed: 23737779
Curr Opin Infect Dis. 2020 Feb;33(1):10-19
pubmed: 31789693
Bone. 2001 Aug;29(2):114-20
pubmed: 11502471
Endocrinology. 2009 Aug;150(8):3603-10
pubmed: 19406946
AIDS. 2015 Nov 28;29(18):2459-64
pubmed: 26355674
Compr Physiol. 2018 Jun 18;8(3):1031-1063
pubmed: 29978896
AIDS. 2020 Mar 1;34(3):351-361
pubmed: 31725429
J Clin Endocrinol Metab. 2007 Apr;92(4):1517-23
pubmed: 17264180
J Clin Endocrinol Metab. 2014 Nov;99(11):4315-20
pubmed: 25093620
HIV Med. 2016 Apr;17(4):255-68
pubmed: 26216031
PLoS One. 2019 Jan 28;14(1):e0209911
pubmed: 30689664
J Clin Endocrinol Metab. 2012 Aug;97(8):E1473-7
pubmed: 22639287
Sci Rep. 2020 Sep 28;10(1):15932
pubmed: 32985609
Cell. 2000 Jan 21;100(2):197-207
pubmed: 10660043
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1474-8
pubmed: 20395593
J Infect Dis. 2015 Oct 15;212(8):1241-9
pubmed: 25948863
Front Endocrinol (Lausanne). 2019 Jan 10;9:794
pubmed: 30687236
J Infect Dis. 2017 Jun 15;215(12):1893-1897
pubmed: 28525596
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11238-E11247
pubmed: 29229807
Diabetes. 2007 Oct;56(10):2533-40
pubmed: 17639021
Clin Infect Dis. 2011 Jul 15;53(2):185-96
pubmed: 21690627
Diabetologia. 2006 Mar;49(3):538-42
pubmed: 16432707
Calcif Tissue Int. 2003 Jul;73(1):27-32
pubmed: 14506951
Osteoporos Int. 2014 Dec;25(12):2685-700
pubmed: 25030653
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32639539
J Bone Miner Res. 2002 Feb;17(2):200-9
pubmed: 11811550
Horm Metab Res. 2012 Nov;44(12):909-13
pubmed: 22581647
J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):433-437
pubmed: 27792683
J Cell Biochem. 2002;85(4):825-36
pubmed: 11968022
J Cell Physiol. 2018 Feb;233(2):1156-1167
pubmed: 28460416
Clin Endocrinol (Oxf). 2012 Jun;76(6):797-801
pubmed: 22151063
Obes Surg. 2019 Sep;29(9):2862-2868
pubmed: 31147821
J Cell Biochem. 2016 Jun;117(6):1419-28
pubmed: 26553151
J Clin Endocrinol Metab. 2014 Apr;99(4):E665-73
pubmed: 24423318
Biochem Biophys Res Commun. 2005 Jun 3;331(2):520-6
pubmed: 15850790
BMC Infect Dis. 2013 Jun 28;13:293
pubmed: 23809140
J Antimicrob Chemother. 2017 May 1;72(5):1456-1461
pubmed: 28175307
Fertil Steril. 2003 Apr;79(4):919-24
pubmed: 12749431
J Bone Miner Res. 2017 Sep;32(9):1945-1955
pubmed: 28650589
AIDS. 2008 Nov 12;22(17):2313-21
pubmed: 18981770
Ann Intern Med. 2010 Jan 19;152(2):93-100
pubmed: 20083828
J Clin Endocrinol Metab. 2001 Nov;86(11):5273-6
pubmed: 11701691
Arch Osteoporos. 2014;9:175
pubmed: 24664472
Clin Endocrinol (Oxf). 2011 Aug;75(2):147-55
pubmed: 21623861
Clin J Am Soc Nephrol. 2014 Jul;9(7):1254-62
pubmed: 24948144
J Womens Health (Larchmt). 2018 Sep;27(9):1162-1169
pubmed: 29608129
Bone Rep. 2020 May 11;12:100279
pubmed: 32455152
AIDS Res Hum Retroviruses. 2009 Dec;25(12):1265-72
pubmed: 20001516
Bone. 2018 Oct;115:68-82
pubmed: 29183784
JBMR Plus. 2018 Jun 20;2(5):247-256
pubmed: 30283906
PLoS One. 2020 Mar 25;15(3):e0230368
pubmed: 32210458
Eur J Endocrinol. 2010 Aug;163(2):265-72
pubmed: 20501596
Nature. 2017 Mar 16;543(7645):385-390
pubmed: 28273060
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):469-76
pubmed: 22895436
Endocr Pract. 2012 Sep-Oct;18(5):758-62
pubmed: 22784851
Calcif Tissue Int. 2012 Jun;90(6):473-80
pubmed: 22527202
J Infect Dis. 2012 Jun;205 Suppl 3:S383-90
pubmed: 22577212
Bone. 2012 Feb;50(2):568-75
pubmed: 21550430
HIV Med. 2008 Feb;9(2):101-10
pubmed: 18257772
J Clin Endocrinol Metab. 2001 May;86(5):1884-7
pubmed: 11344177
Physiol Res. 2008;57 Suppl 1:S143-S151
pubmed: 18271682